New York, June 1, 2026, 15:06 (EDT)
Cellectis S.A. ADRs slipped Monday, with the U.S.-listed gene-editing biotech trading near session lows. Shares last quoted at $3.44, down 8 cents, or 2.3%. Cellectis opened at $3.55, hit a high of $3.69, and traded only 37,375 shares in light action.
Cellectis shares dropped in a slumping biotech sector, with no new disclosure from the company. The SPDR S&P Biotech ETF finished down roughly 1.7%. The iShares Nasdaq Biotechnology ETF slid 1.4%. Cellectis’ most recent update on its press page was a May 20 announcement about its June 25 annual meeting.
That’s relevant this week as Cellectis has some near-term but not imminent events. The company heads to the Jefferies Global Healthcare Conference from June 2 to June 4, and it’s planning clinical updates tied to the European Hematology Association meeting. Blood-cancer data from EHA often swings trading for smaller drug makers.
Cellectis is a clinical-stage firm, so its drugs are still in trials and aren’t sold on the market. The company works on allogeneic CAR-T, which uses donor immune cells, not patient cells. These are engineered to fight cancer and designed to be an “off-the-shelf” therapy.
Cellectis said it plans to share Phase 1 data for lasme-cel, its CD22-targeting allogeneic CAR-T, in relapsed or refractory B-cell acute lymphoblastic leukemia, at EHA on June 13. Adrian Kilcoyne, chief medical officer, said trial responses “offer hope for these patients.” The pivotal Phase 2 work is still going. Cellectis
Cellectis reported first-quarter cash, cash equivalents and fixed-term deposits at $188 million as of March 31, enough to fund the company into the fourth quarter of 2027. In the same update, the company set the first interim analysis for its pivotal Phase 2 BALLI-01 trial of lasme-cel and a full Phase 1 data readout for eti-cel for the fourth quarter of 2026. CEO André Choulika called late 2026 Cellectis’ “defining moment.” GlobeNewswire
Allogene Therapeutics is the read-across here. In April, Cellectis said its cema-cel candidate, first made as UCART19 at Cellectis, showed minimal residual disease negativity in 58.3% of treated patients, compared to 16.7% in the observation group, according to an interim analysis. Cema-cel is licensed to Servier and then sublicensed to Allogene in some regions. Cellectis says it could get up to $340 million in milestones and low double-digit royalties on CD19 drugs like cema-cel.
Barclays started Cellectis with an overweight and set a $9 target last week, Investing.com said. That target is higher than where the stock traded Monday, but it didn’t move the needle much as the biotech trade stayed wary.
Allogeneic CAR-T is still a data play. There is no approved product yet. Leerink Partners analyst Daina Graybosch told Fierce Biotech that “the home run in allo” is showing it can do what patient-derived CAR-T can’t. AvenCell CEO Andrew Schiermeier was even sharper: “The only thing that saves us is data.” Fierce Biotech
Traders are watching just a few dates for now. Jefferies could give some management comments this week. EHA has its clinical spotlight on June 13. Then there’s the shareholder meeting on June 25. But the main question on the stock holding up at higher valuations probably gets pushed to the fourth-quarter readouts.
